Literature DB >> 25688110

The expanding role of mTOR in cancer cell growth and proliferation.

Marie Cargnello1, Joseph Tcherkezian2, Philippe P Roux3.   

Abstract

The mechanistic/mammalian target of rapamycin (mTOR) is a conserved protein kinase that controls several anabolic processes required for cell growth and proliferation. As such, mTOR has been implicated in an increasing number of pathological conditions, including cancer, obesity, type 2 diabetes and neurodegeneration. As part of the mTOR complex 1 (mTORC1), mTOR regulates cell growth by promoting the biosynthesis of proteins, lipids and nucleic acids. Several mTORC1 substrates have been shown to regulate protein synthesis, including the eukaryotic initiation factor 4E (eIF4E)-binding proteins (4E-BPs) and the ribosomal S6 kinases (S6Ks) 1 and 2. In this work, we focus on the signalling pathways that lie both upstream and downstream of mTORC1, as well as their relevance to human pathologies. We further discuss pharmacological approaches that target mTOR and their applications for the treatment of cancer.
© The Author 2015. Published by Oxford University Press on behalf of the UK Environmental Mutagen Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25688110      PMCID: PMC5943824          DOI: 10.1093/mutage/geu045

Source DB:  PubMed          Journal:  Mutagenesis        ISSN: 0267-8357            Impact factor:   3.000


  105 in total

1.  ERK1/2 phosphorylate Raptor to promote Ras-dependent activation of mTOR complex 1 (mTORC1).

Authors:  Audrey Carriere; Yves Romeo; Hugo A Acosta-Jaquez; Julie Moreau; Eric Bonneil; Pierre Thibault; Diane C Fingar; Philippe P Roux
Journal:  J Biol Chem       Date:  2010-11-11       Impact factor: 5.157

2.  Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism.

Authors:  K Hara; K Yonezawa; Q P Weng; M T Kozlowski; C Belham; J Avruch
Journal:  J Biol Chem       Date:  1998-06-05       Impact factor: 5.157

3.  Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors.

Authors:  Beverly L Falcon; Sharon Barr; Prafulla C Gokhale; Jeyling Chou; Jennifer Fogarty; Philippe Depeille; Mark Miglarese; David M Epstein; Donald M McDonald
Journal:  Cancer Res       Date:  2011-03-01       Impact factor: 12.701

4.  The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity.

Authors:  David Shahbazian; Philippe P Roux; Virginie Mieulet; Michael S Cohen; Brian Raught; Jack Taunton; John W B Hershey; John Blenis; Mario Pende; Nahum Sonenberg
Journal:  EMBO J       Date:  2006-06-08       Impact factor: 11.598

5.  Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast.

Authors:  J Heitman; N R Movva; M N Hall
Journal:  Science       Date:  1991-08-23       Impact factor: 47.728

6.  Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome.

Authors:  Suchithra Menon; Christian C Dibble; George Talbott; Gerta Hoxhaj; Alexander J Valvezan; Hidenori Takahashi; Lewis C Cantley; Brendan D Manning
Journal:  Cell       Date:  2014-02-13       Impact factor: 41.582

7.  Akt regulates growth by directly phosphorylating Tsc2.

Authors:  Christopher J Potter; Laura G Pedraza; Tian Xu
Journal:  Nat Cell Biol       Date:  2002-09       Impact factor: 28.824

8.  Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue.

Authors:  J Chen; X F Zheng; E J Brown; S L Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

9.  An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1.

Authors:  Carson C Thoreen; Seong A Kang; Jae Won Chang; Qingsong Liu; Jianming Zhang; Yi Gao; Laurie J Reichling; Taebo Sim; David M Sabatini; Nathanael S Gray
Journal:  J Biol Chem       Date:  2009-01-15       Impact factor: 5.157

10.  Regulation of TORC1 in response to amino acid starvation via lysosomal recruitment of TSC2.

Authors:  Constantinos Demetriades; Nikolaos Doumpas; Aurelio A Teleman
Journal:  Cell       Date:  2014-02-13       Impact factor: 41.582

View more
  61 in total

1.  Perspective: The Potential Role of Essential Amino Acids and the Mechanistic Target of Rapamycin Complex 1 (mTORC1) Pathway in the Pathogenesis of Child Stunting.

Authors:  Richard D Semba; Indi Trehan; Marta Gonzalez-Freire; Klaus Kraemer; Ruin Moaddel; M Isabel Ordiz; Luigi Ferrucci; Mark J Manary
Journal:  Adv Nutr       Date:  2016-09-15       Impact factor: 8.701

2.  Role of mTOR complex in IGF-1 induced neural differentiation of DPSCs.

Authors:  Dan Huang; Shuling Shen; Ming Cai; Lin Jin; Jun Lu; Ke Xu; Jinlong Zhang; Guijuan Feng; Yingzi Hu; Ke Zheng; Xingmei Feng
Journal:  J Mol Histol       Date:  2019-05-02       Impact factor: 2.611

3.  [MicroRNA-152 and microRNA-448 inhibit proliferation of colorectal cancer cells in vitro by targeting Rictor].

Authors:  Jie Zhang; Zengsheng Han; Lixin Dong; Zhen Li; Kun Li; Ming Shi; Zhiwei Liu; Jian Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-05-30

4.  Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations.

Authors:  Tyler M Foley; Susan N Payne; Cheri A Pasch; Alex E Yueh; Dana R Van De Hey; Demetra P Korkos; Linda Clipson; Molly E Maher; Kristina A Matkowskyj; Michael A Newton; Dustin A Deming
Journal:  Mol Cancer Res       Date:  2017-02-09       Impact factor: 5.852

5.  Expression of the miR-150 tumor suppressor is restored by and synergizes with rapamycin in a human leukemia T-cell line.

Authors:  Katie Podshivalova; Eileen A Wang; Traver Hart; Daniel R Salomon
Journal:  Leuk Res       Date:  2018-09-22       Impact factor: 3.156

6.  Inactivation of the LKB1-AMPK signaling pathway does not contribute to salivary gland tumor development - a short report.

Authors:  Natascha Cidlinsky; Giada Dogliotti; Tobias Pukrop; Rudolf Jung; Florian Weber; Michael P Krahn
Journal:  Cell Oncol (Dordr)       Date:  2016-08-01       Impact factor: 6.730

7.  Metformin Has Positive Therapeutic Effects in Colon Cancer and Lung Cancer.

Authors:  DeAnna Henderson; Danielle Frieson; Jeffrey Zuber; Solomon S Solomon
Journal:  Am J Med Sci       Date:  2017-05-19       Impact factor: 2.378

Review 8.  Prognostic and predictive role of the PI3K-AKT-mTOR pathway in neuroendocrine neoplasms.

Authors:  P Gajate; T Alonso-Gordoa; O Martínez-Sáez; J Molina-Cerrillo; E Grande
Journal:  Clin Transl Oncol       Date:  2017-11-09       Impact factor: 3.405

9.  Cell size and fat content of dietary-restricted Caenorhabditis elegans are regulated by ATX-2, an mTOR repressor.

Authors:  Daniel Z Bar; Chayki Charar; Jehudith Dorfman; Tam Yadid; Lionel Tafforeau; Denis L J Lafontaine; Yosef Gruenbaum
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-25       Impact factor: 11.205

Review 10.  HSF1: Guardian of Proteostasis in Cancer.

Authors:  Chengkai Dai; Stephen Byers Sampson
Journal:  Trends Cell Biol       Date:  2015-11-18       Impact factor: 20.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.